Establishment Labs, a NYC-based global medical device company focused on breast surgery technologies, closed an $18m financing round.
Backers included Kilowatt Capital and Florence Capital Advisors.
The company intends to use the funds to launch Motiva Implants® and Puregraft® in some of the largest markets worldwide.
Led by Juan José Chacón Quirós, CEO, Establishment Labs is a breast implant and medical technology company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast and body shaping implants. Its CE-marked Motiva Implants® line of silicone breast implants utilizing medical-grade silicone is sold in more than 60 countries worldwide. Puregraft®’s FDA cleared and CE-Marked technology provides plastic surgeons with purified fat for reinjection on the sterile field. The technology is used in hospitals and clinics around the world.
Over the last six months, the company has received regulatory clearances in Russia, Australia, Saudi Arabia, Israel, Vietnam and Brazil -among others- and is currently in the process of scaling up production capacity at its manufacturing plant in Costa Rica.